Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2006

01-11-2006 | Epidemiology

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families

Authors: Giuseppe Giannini, Carlo Capalbo, Elisabetta Ristori, Enrico Ricevuto, Tina Sidoni, Amelia Buffone, Enrico Cortesi, Paolo Marchetti, Giovanni Scambia, Silverio Tomao, Christian Rinaldi, Massimo Zani, Sergio Ferraro, Luigi Frati, Isabella Screpanti, Alberto Gulino

Published in: Breast Cancer Research and Treatment | Issue 1/2006

Login to get access
Metadata
Title
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families
Authors
Giuseppe Giannini
Carlo Capalbo
Elisabetta Ristori
Enrico Ricevuto
Tina Sidoni
Amelia Buffone
Enrico Cortesi
Paolo Marchetti
Giovanni Scambia
Silverio Tomao
Christian Rinaldi
Massimo Zani
Sergio Ferraro
Luigi Frati
Isabella Screpanti
Alberto Gulino
Publication date
01-11-2006
Published in
Breast Cancer Research and Treatment / Issue 1/2006
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9225-9

Other articles of this Issue 1/2006

Breast Cancer Research and Treatment 1/2006 Go to the issue

Epidemiology

Intensity of diagnostic and treatment activities during the end of life of patients with advanced breast cancer

Preclinical Study

Secreted Frizzled Related Protein 2 (sFRP2) Decreases Susceptibility to UV-Induced Apoptosis in Primary Culture of Canine Mammary Gland Tumors by NF-κB Activation or JNK Suppression

Clinical trial

Estrogen Receptor Expression in Benign Breast Ductal Cells Obtained from Random Periareolar Fine Needle Aspiration Correlates with Menopausal Status and Cytomorphology Index Score

CLINICAL STUDY

Cosmetic outcomes following breast conservation therapy: in search of a reliable scale

Preclinical Study

Proteasome Inhibitors Induce a p38 Mitogen-activated Protein Kinase (MAPK)-dependent Anti-apoptotic Program Involving MAPK Phosphatase-1 and Akt in Models of Breast Cancer

Clinical Trial

Premature Menopause in Patients with BRCA1 Gene Mutation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits